Key result
Higher Galectin-3 links to ~18% higher hypertension odds but fails to predict incident disease.
Why the study?
Circulating Galectin-3 is associated with heart failure, atrial fibrillation, chronic kidney disease, and mortality, and recent evidence suggests it may also modulate cardiometabolic traits such as adiposity, insulin resistance, and hyperglycemia. The associations of blood Galectin-3 concentrations with cardiometabolic disease traits in the community were examined.
Are higher circulating Galectin-3 concentrations associated with cross-sectional and incident cardiometabolic disease traits in a community-based cohort?
Cohort (n=2,946)
No
Are higher circulating Galectin-3 concentrations associated with cross-sectional and incident cardiometabolic disease traits in a community-based cohort?
Answers are grounded in this paper and cite their sources.
Although circulating Galectin-3 correlates cross-sectionally with abdominal adiposity, dyslipidemia, and hypertension, it does not independently predict incident cardiometabolic disease after accounting for traditional clinical risk factors.
BACKGROUND: Circulating Galectin-3 (Gal-3) concentrations are associated with an increased incidence of heart failure, atrial fibrillation, chronic kidney disease, and mortality. Recent evidence suggests that Gal-3 may also be an important modulator of cardiometabolic traits such as adiposity, insulin resistance, and hyperglycemia. We examined the associations of blood Gal-3 concentrations and cardiometabolic disease traits in the Framingham Heart Study. METHODS AND RESULTS: In cross-sectional analyses of 2946 Framingham Heart Study participants (mean age 59 years, 55% women), higher Gal-3 concentrations were associated with higher body mass index, waist circumference, and triglycerides (P<0.0001 for all). Higher Gal-3 was associated with greater odds of obesity (multivariable-adjusted odds ratio 1.16 per 1-SD increase in log-Gal-3, 95% CI 1.06-1.28, P=0.002) and hypertension (odds ratio 1.18, 95% CI 1.07-1.29, P=0.0006). In prospective analyses, Gal-3 was associated with incident metabolic syndrome (hazard ratio 1.22, 95% CI 1.10-1.36, P=0.0002) and diabetes (hazard ratio 1.21, 95% CI 1.04-1.41, P=0.02), in age- and sex-adjusted, but not multivariable-adjusted models. CONCLUSIONS: In this large, community-based sample, circulating Gal-3 was associated with abdominal adiposity, dyslipidemia, and hypertension in cross-sectional analyses, but Gal-3 did not predict incident cardiometabolic disease after adjusting for cardiometabolic risk factors. Future investigations should focus on further elucidating mechanisms linking Gal-3 with cardiometabolic disease and on assessing whether modulation of the Gal-3 pathway might have positive cardiometabolic effects.
No takes yet. Share an insight, caveat, or question.
Nayor et al. (2016) conducted a cohort in Cardiometabolic disease traits in the community (n=2,946). Circulating Galectin-3 concentration (per 1-SD increase in log-Gal-3) was evaluated on Cross-sectional multivariable-adjusted odds of hypertension (OR 1.18, 95% CI 1.07-1.29, p=0.0006). Higher Galectin-3 was cross-sectionally associated with hypertension and obesity, but did not predict incident cardiometabolic disease in adjusted models.
Synapse has enriched 10 related papers. Consider them for comparative context: